Kathleen Aertgeerts, Ph.D. Senior Director of Structural Biology
Dr. Aertgeerts joined DNS in 2012, bringing over 20 years of experience in Structural Biology with more than 12 years dedicated to Structure-Guided Drug Discovery across several therapeutic areas. Prior to DNS, Dr. Aertgeerts worked as Director of Structural Biology at Takeda California, where her team provided crystallography support for Takeda's affiliates in the US, Europe and Japan. Before Takeda, Dr. Aertgeerts held scientific roles with increasing responsibility in Structural Biology at Syrrx, a biotechnology company that pioneered nanovolume High-Throughput Crystallography. During her time at Syrrx and Takeda, Dr. Aertgeerts held several project leadership roles in the therapeutic areas of inflammation, metabolic and cardiovascular diseases that led to the successful discovery of multiple drug candidates currently in various stages of preclinical and clinical development. One of her contributions in Structural Biology led to the discovery of NESINA (generic name Alogliptin), currently approved in multiple countries for the treatment of type 2 diabetes. Dr. Aertgeerts earned her Ph.D. in Crystallography from the Catholic University of Leuven (KUL), Belgium and did post-doctoral work at The Scripps Research Institute (TSRI).